Human papillomavirus vaccine introduction in low-income and middle-income countries: Guidance on the use of cost-effectiveness models

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Jit, Mark ^a   Demarteau, Nadia ^b   Elbasha, Elamin ^c   Ginsberg, Gary ^d   Kim, Jane ^e   Praditsitthikorn, Naiyana ^f   Sinanovic, Edina ^g   Hutubessy, Raymond ^h  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MINISTRY OF HEALTH   (Israel)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANALYTIC METHOD; ARTICLE; COST EFFECTIVENESS ANALYSIS; GLAXOSMITHKLINE MODEL; HARVARD MODEL; HUMAN; INCIDENCE; LOWEST INCOME GROUP; MERCK MODEL; MIDDLE INCOME GROUP; PAPILLOMAVIRUS INFECTION; PREVALENCE; SOCIAL STATUS; SOUTH AFRICAN MODEL; THAI MODEL; UTERINE CERVIX CANCER; VACCINATION; WHO CHOOSING INTERVENTIONS THAT ARE COST EFFECTIVE MODEL; ADOLESCENT; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; FEMALE; IMMUNOLOGY; STATISTICAL MODEL; UTERINE CERVIX TUMOR;

ADOLESCENT; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HUMANS; MODELS, STATISTICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 79955838839     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-54     Document Type: Article

References (29)

1. International Agency for Research on Cancer World Cancer Report, 2008. 2008, Lyon: IARC Press, International Agency for Research on Cancer.
2. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356:1915-1927. FUTURE II Study Group.
3. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314. 10.1016/S0140-6736(09)61248-4, 19586656.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259.
5. Adams M, Jasani B, Fiander A. Prophylactic HPV vaccination for women over 18 years of age. Vaccine 2009, 27:3391-3394. 10.1016/j.vaccine.2009.01.067, 19200838.
6. World Health Organization Vaccine Introduction Guidelines. Adding a Vaccine to a National Immunization Programme: Decision and Implementation. 2005, Geneva: World Health Organization, World Health Organization.
7. World Health Organization Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009, 84:118-131. World Health Organization.
8. Beutels P, Jit M. A brief history of economic evaluation for human papillomavirus vaccination policy. Sex Health 2010, 7:352-358. 10.1071/SH10018, 20719227.
9. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56:1-24.
10. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'shea MK, Xavier BF, de Sanjose S, Franco EL. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25:6257-6270. 10.1016/j.vaccine.2007.05.058, 17606315.
11. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97:1322-1328. 10.1038/sj.bjc.6604023, 2360471, 17923869.
12. Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine 2009, 27:6196-6202. 10.1016/j.vaccine.2009.08.004, 19698807.
13. Ginsberg GM, Edejer TT, Lauer JA, Sepulveda C. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. Vaccine 2009, 27:6060-6079. 10.1016/j.vaccine.2009.07.026, 19647813.
14. Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-4093. 10.1016/j.vaccine.2008.04.053, 18550229.
15. Andrus JK, Toscano CM, Lewis M, Oliveira L, Ropero AM, Davila M, Fitzsimmons JW. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 2007, 122:811-816. 1997250, 18051674.
16. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28:88-100. 10.1093/epirev/mxj006, 16740585.
17. Insinga RP, Dasbach EJ, Elbasha EH. Structural differences among cost-effectiveness models of human papillomavirus vaccines. Expert Rev Vaccines 2008, 7:895-913. 10.1586/14760584.7.7.895, 18767941.
18. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009, 27:127-147. 10.2165/00019053-200927020-00004, 19254046.
19. Puig-Junoy J, Lopez-Valcarcel BG. Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. Prev Med 2009, 48:444-448. 10.1016/j.ypmed.2009.02.011, 19232368.
20. Techakehakij W, Feldman RD. Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review. Vaccine 2008, 26:6258-6265. 10.1016/j.vaccine.2008.09.036, 18835313.
21. Brisson M, Van d V, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009, 12:343-351. 10.1159/000214924, 19684446.
22. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(Suppl 10):K76-K86. 2769256, 18847560.
23. Ferko N, Postma M, Gallivan S, Kruzikas D, Drummond M. Evolution of the health economics of cervical cancer vaccination. Vaccine 2008, 26(Suppl 5):F3-15.
24. Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007, 7:289-296. 10.1016/S1473-3099(07)70083-X, 17376386.
25. Tangcharoensathien V, Limwattananon S, Chaugwon R, Praditsittikorn N, Teerawattananon Y, Tantavess S. Research for Development of an Optimal Policy Strategy for Prevention and Control of Cervical Cancer in Thailand. Research report submitted to the World Bank. 2008, Nonthaburi, Thailand: International Health Policy Program, Thailand (IHPP) and Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health.
26. Praditsitthikorn N, Teerawattananon Y, Tantivess S, Limwattananon S, Riewpaiboon A, Chichareon S, Ieumwananonthachai N, Tangcharoensathien V. Economic evaluation of policy options for prevention and control of cervical cancer in Thailand. Pharmacoeconomics (in press) 2011,
27. Elbasha EH, Dasbach EJ, Insinga RP. Model for Assessing Human Papillomavirus Vaccination Strategies. Emerg Infect Dis 2007, 13:28-41. 10.3201/eid1301.060438, 2725801, 17370513.
28. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401. 10.1186/1471-2458-9-401, 2777872, 19878578.
29. WHO/ICO Information Centre on Human Papilloma Virus (HPV) and Cervical Cancer. , http://www.who.int/hpvcentre/en/